Öz

Objective: This study aims to assess the frequency of drug-related problems (DRPs) related to antimicrobial drugs in the ICU and to examine changes in the use of antibiotics in the ‘Reserve’ group of the World Health Organization (WHO) AWaRe classification during the antimicrobial stewardship (AMS) team intervention, including the clinical pharmacist.

Methods: In this single-center intervention study, the pre-intervention period between November 2021 and August 2022 and the post-intervention period between November 2022 and August 2023 were evaluated. In the post-intervention period, a clinical pharmacist was also included in the AMS team. Post-intervention medication-related problems (DRPs) were categorized using only the “problem” and “cause” domains of the Pharmaceutical Care Network Europe (PCNE) V9.1 classification system. Additionally, recommendations and their acceptance rates were recorded. The antibiotic use density of the ‘Reserve’ group, defined in the WHO AWaRe classification, was evaluated in terms of days of therapy (DOT) per 1000 patient-days.

Results: After the intervention, 175 DRPs were detected in 67.1% of 173 patients; 70% were related to antimicrobial drugs. The 90.1% of the interventions suggested by the clinical pharmacist were evaluated and accepted by infectious diseases and intensive care specialists. The total use of “Reserve” group antibiotics decreased, but not significantly; significant decreases were observed for some agents such as linezolid and daptomycin.

Conclusion: Multidisciplinary antimicrobial stewardship practices involving the clinical pharmacist can contribute to the prevention of antimicrobial resistance development by facilitating the detection and solution of DRPs, especially by reducing the use of ‘Reserve’ group antimicrobials.

Anahtar Kelimeler: antimicrobial resistance, antimicrobial stewardship, intensive care unit

Referanslar

  1. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399:629-55. https://doi.org/10.1016/S0140-6736(21)02724-0
  2. Isler B, Keske Ş, Aksoy M, et al. Antibiotic overconsumption and resistance in Turkey. Clin Microbiol Infect. 2019;25:651-3. https://doi.org/10.1016/j.cmi.2019.02.024
  3. Barrett J, Edgeworth J, Wyncoll D. Shortening the course of antibiotic treatment in the intensive care unit. Expert Rev Anti Infect Ther. 2015;13:463-71. https://doi.org/10.1586/14787210.2015.1008451
  4. Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med. 2000;162:505-11. https://doi.org/10.1164/ajrccm.162.2.9909095
  5. Roberts JA, De Waele JJ, Dimopoulos G, et al. DALI: defining antibiotic levels in intensive care unit patients: a multi-centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic. BMC Infect Dis. 2012;12:152. https://doi.org/10.1186/1471-2334-12-152
  6. Ng TM, Heng ST, Chua BH, et al. Sustaining antimicrobial stewardship in a high-antibiotic resistance setting. JAMA Netw Open. 2022;5:e2210180. https://doi.org/10.1001/jamanetworkopen.2022.10180
  7. World Health Organization (WHO). WHO releases the 2019 AWaRe classification of antibiotics. Geneva: WHO; 2019. Available at: https://www.who.int/news/item/01-10-2019-who-releases-the-2019-aware-classification-antibiotics
  8. Newland JG, Stach LM, De Lurgio SA, et al. Impact of a prospective-audit-with-feedback antimicrobial stewardship program at a children’s hospital. J Pediatric Infect Dis Soc. 2012;1:179-86. https://doi.org/10.1093/jpids/pis054
  9. Mehta JM, Haynes K, Wileyto EP, et al. Comparison of prior authorization and prospective audit with feedback for antimicrobial stewardship. Infect Control Hosp Epidemiol. 2014;35:1092-9. https://doi.org/10.1086/677624
  10. Hashimoto M, Asai S, Umezawa K, et al. Impact of ward pharmacist-led antimicrobial stewardship in intensive care units. J Chemother. 2023;35:188-97. https://doi.org/10.1080/1120009X.2022.2087652
  11. Yu J, Liu Y, Qu R, et al. Evaluation of a clinical pharmacist-led antimicrobial stewardship program in a neurosurgical intensive care unit: a pre-and post-intervention cohort study. Front Pharmacol. 2023;14:1263618. https://doi.org/10.3389/fphar.2023.1263618
  12. Li Z, Cheng B, Zhang K, et al. Pharmacist-driven antimicrobial stewardship in intensive care units in East China: a multicenter prospective cohort study. Am J Infect Control. 2017;45:983-9. https://doi.org/10.1016/j.ajic.2017.02.021
  13. Khdour MR, Hallak HO, Aldeyab MA, et al. Impact of antimicrobial stewardship programme on hospitalized patients at the intensive care unit: a prospective audit and feedback study. Br J Clin Pharmacol. 2018;84:708-15. https://doi.org/10.1111/bcp.13486
  14. Gu H, Sun L, Sheng B, et al. Benefits of pharmacist intervention in the critical care patients with infectious diseases: a propensity score matching retrospective cohort study. Aust Crit Care. 2023;36:933-9. https://doi.org/10.1016/j.aucc.2022.12.011
  15. Buyle FM, Wallaert M, Beck N, et al. Implementation of a multidisciplinary infectious diseases team in a tertiary hospital within an antimicrobial stewardship program. Acta Clin Belg. 2014;69:320-6. https://doi.org/10.1179/2295333714Y.0000000045
  16. T.C. Sağlık Bakanlığı, Halk Sağlığı Genel Müdürlüğü. Türkiye sağlık hizmeti ile ilişkili enfeksiyonları önleme ve kontrol programı (2019-2024). Ankara: T.C. Sağlık Bakanlığı; 2019. Available at: https://hsgm.saglik.gov.tr/depo/Yayinlarimiz/Programlar/Turkiye_Saglik_Hizmeti_Ile_Iliskili_Enfeksiyonlari_Onleme_ve_Kontrol_Programi.pdf
  17. Shamas N, Stokle E, Ashiru-Oredope D, Wesangula E. Challenges of implementing antimicrobial stewardship tools in low to middle income countries (LMICs). Infect Prev Pract. 2023;5:100315. https://doi.org/10.1016/j.infpip.2023.100315
  18. Albayrak A, Başgut B, Bıkmaz GA, Karahalil B. Clinical pharmacist assessment of drug-related problems among intensive care unit patients in a Turkish university hospital. BMC Health Serv Res. 2022;22:79. https://doi.org/10.1186/s12913-022-07494-5
  19. Ayhan YE, Karakurt S, Sancar M. The effect of the clinical pharmacist in minimizing drug-related problems and related costs in the intensive care unit in Turkey: a non-randomized controlled study. J Clin Pharm Ther. 2022;47:1867-74. https://doi.org/10.1111/jcpt.13784
  20. Özger HS, Fakıoğlu DM, Erbay K, Albayrak A, Hızel K. Inapropriate use of antibiotics effective against gram positive microorganisms despite restrictive antibiotic policies in ICUs: a prospective observational study. BMC Infect Dis. 2020;20:289. https://doi.org/10.1186/s12879-020-05005-7
  21. Sisay M, Hagos B, Edessa D, Tadiwos Y, Mekuria AN. Polymyxin-induced nephrotoxicity and its predictors: a systematic review and meta-analysis of studies conducted using RIFLE criteria of acute kidney injury. Pharmacol Res. 2021;163:105328. https://doi.org/10.1016/j.phrs.2020.105328
  22. Ballı FN, Ekinci PB, Kurtaran M, et al. Battle of polymyxin-induced nephrotoxicity: polymyxin B versus colistin. Int J Antimicrob Agents. 2024;63:107035. https://doi.org/10.1016/j.ijantimicag.2023.107035
  23. Albayrak A, Özger HS, Başgut B, Aygencel Bıkmaz G, Karahalil B. Impact of clinical pharmacist’s interventions on clinical outcomes in appropriate use of colistin: a prospective pre-post intervention study. J Chemother. 2023;35:712-20. https://doi.org/10.1080/1120009X.2023.2196916

Telif hakkı ve lisans

Telif hakkı © 2026 Yazar(lar). Açık erişimli bu makale, orijinal çalışmaya uygun şekilde atıfta bulunulması koşuluyla, herhangi bir ortamda veya formatta sınırsız kullanım, dağıtım ve çoğaltmaya izin veren Creative Commons Attribution License (CC BY) altında dağıtılmıştır.

Nasıl atıf yapılır?

1.
Pehlivanlı A, Yanık Yalçın T, Yeşiler Fİ, Sarı N, Şahintürk H, Kurt Azap Ö, et al. Antimicrobial stewardship practices in the intensive care unit: a pre–post interventional study. Turk J Intensive Care. 2026;24(3):165-172. https://doi.org/10.63729/TJIC.2026.700